CoChat

Online searches for SGLT-2 inhibitors and GLP-1 receptor agonists correlate with prescription rates in the United States: An infodemiological study

Open access
Dzaye, Omar, Berning, Philipp, Razavi, Alexander C., Adhikari, Rishav, Jha, Kunal, Nasir, Khurram, Ayers, John W., Mortensen, Martin Bødtker, Blaha, Michael J. · 2022 · Frontiers in Cardiovascular Medicine
Cited by 27

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Several clinical trials have demonstrated that many SGLT-2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1 RA) can reduce the risk of cardiovascular events in patients with Type 2 diabetes and atherosclerotic cardiovascular disease. Recent reports indicate an underutilization of new cardiometabolic drugs, including SGLT2i and GLP-1 RA. We aimed to evaluate the use of online search volumes to reflect United States prescription rates. A repeated cross-sectional analysis of Google search volumes and corresponding data from the IQVIA National Prescription Audit (NPA) of pharmacy dispensing of newly prescribed drugs was performed. Monthly data for online searches and prescription between January 1, 2016 and December 31, 2021 were collected for selected SGLT2i and GLP-1 RA. Prescription data for drugs classes (SGLT2i and GLP-1 RA) and individual drugs were calculated as the total of queried data for branded drug names. Trends were analyzed for visual and quantitative correlation as well as predictive patterns. Overall, online searches increased by 157.6% (95% CI: 142.2–173.1%) and 295.2% (95% CI: 257.7–332.6%) for SGLT2i and GLP-1RA between 2016 and 2021. Prescription rates raised by 114.6% (95% CI: 110.8–118.4%) and 221.0% (95% CI: 212.1–229.9%) for SGLT2i and GLP-1RA for this period. Correlation coefficients (range 0.86–0.99) were strongest for drugs with growing number of prescriptions, for example dapagliflozin, empagliflozin, ertugliflozin, dulaglutide, and semaglutide. Online searches might represent an additional tool to monitor the utilization trends of cardiometabolic drugs. Associations were strongest for drugs with reported cardioprotective effect. Thus, trends in online searches complement conventionally acquired data to reflect and forecast prescription trends of cardiometabolic drugs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fcvm.2022.936651

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 27

Metadata

Authors
Dzaye, O., Berning, P., Razavi, A. C., Adhikari, R., Jha, K., Nasir, K., Ayers, J. W., Mortensen, M. B., & Blaha, M. J.
Venue
Frontiers in Cardiovascular Medicine
Published
2022-07-29
Volume
9
Pages
936651-936651
ISSN
2297-055X (ISSN-L)
OpenAlex
W4288423816
Cited by
27
References
8
FWCI
3.61
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Online searches for SGLT-2 inhibitors and GLP-1 receptor agonists correlate with prescription rates in the United States: An infodemiological study. https://app.cochat.ai/papers/10.3389/fcvm.2022.936651
The paper
Dzaye, O., Berning, P., Razavi, A. C., Adhikari, R., Jha, K., Nasir, K., Ayers, J. W., Mortensen, M. B., & Blaha, M. J. (2022). Online searches for SGLT-2 inhibitors and GLP-1 receptor agonists correlate with prescription rates in the United States: An infodemiological study. Frontiers in Cardiovascular Medicine. https://doi.org/10.3389/fcvm.2022.936651

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.